Key facts
- Arthex Biotech’s last known valuation is $11.9M (Jul 2020).
- It has raised $95.1M; the latest was Later Stage VC ($87.0M) in Sep 2025.
- Notable investors include Bpifrance, European Innovation Council, INNVIERTE SICC, CDTI Innvierte, Caixa Capital Risc — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Arthex Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Arthex Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arthex Biotech
Developer of oligonucleotide therapeutics designed for the treatment of diseases with unmet needs. The company develops drugs and therapies that are designed to treat a variety of disorders, enabling medical professionals to get access to therapy that helps treat patients suffering from genetic diseases, rare diseases, and diseases with high medical needs.
- Sector
- Healthcare
- HQ
- Valencia, Spain
- Founded
- 2019
- Employees
- 25
- Website
- arthexbiotech.com/
- Ownership
- Privately Held (backing)
Arthex Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arthex Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arthex Biotech in its N-PORT filings yet. We sweep new filings monthly.